Obstetrics/Gynecology
RSSArticles
-
Adding to Survival ( Again): Cervix Cancer
Bevacizumab added to chemotherapy, particularly paclitaxel and cisplatin, was efficacious in all response outcomes (objective response, progression-free survival, and overall survival) without diminution in quality of life or unacceptable toxicity. -
Infectious Disease Malpractice: The $1.2 Million Miscommunication
-
Two-step Screening for Ovarian Cancer: A ‘Scissor-step’ Forward?
-
Improving Adherence: Who's Doing the Work?
Approximately 50% of patients with chronic illnesses do not adhere to indicated medications, treatment regimens, and healthy lifestyle changes.
-
Primary Care Reports - Full March 2014 Issue in PDF
-
Side Effects of Opioids
Constipation is the most commonly reported side effect with opioid therapy. Tolerance does not generally develop. Most patients on chronic opioid therapy require prophylaxis -
Contraception focus: Combined hormones
Results of the 2013 Contraceptive Technology Update Contraception Survey indicate that use of the NuvaRing contraceptive vaginal ring and the Evra contraceptive patch is consistent with 2012's figures. -
Extended OC use, Quick Start has arrived
Responses to the 2013 Contraceptive Technology Update Contraception Survey indicate that many clinicians have moved to remove one hurdle to contraception by adopting the Quick Start method of method initiation. -
Contraceptive Technology Update - April 2014 Issue in PDF
-
Contraceptive implant makes inroads as birth control option
Women continue to choose long-acting reversible contraceptive (LARC) methods, say respondents to the 2013 Contraceptive Technology Update Contraception Survey.